메뉴 건너뛰기




Volumn 13, Issue 5, 2011, Pages 461-466

Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms: A paper from the 2010 William Beaumont Hospital Symposium on Molecular Pathology

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; THROMBOPOIETIN RECEPTOR;

EID: 82755191711     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2011.05.007     Document Type: Review
Times cited : (26)

References (59)
  • 3
    • 38349060667 scopus 로고    scopus 로고
    • The history of myeloproliferative disorders: Before and after Dameshek
    • Tefferi A: The history of myeloproliferative disorders: before and after Dameshek. Leukemia 2008, 22:3-13
    • (2008) Leukemia , vol.22 , pp. 3-13
    • Tefferi, A.1
  • 4
    • 77954581139 scopus 로고    scopus 로고
    • Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
    • Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138
    • (2010) Leukemia , vol.24 , pp. 1128-1138
    • Tefferi, A.1
  • 6
    • 33749325187 scopus 로고    scopus 로고
    • Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation
    • DOI 10.1182/blood-2006-02-005751
    • Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, Sekeres MA, Maciejewski JP: Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006, 108:2173-2181 (Pubitemid 44497497)
    • (2006) Blood , vol.108 , Issue.7 , pp. 2173-2181
    • Szpurka, H.1    Tiu, R.2    Murugesan, G.3    Aboudola, S.4    Hsi, E.D.5    Theil, K.S.6    Sekeres, M.A.7    Maciejewski, J.P.8
  • 8
    • 70449520449 scopus 로고    scopus 로고
    • Myeloproliferative neoplasms: Contemporary diagnosis using histology and genetics
    • Tefferi A, Skoda R, Vardiman JW: Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nature Rev 2009, 6:627-637
    • (2009) Nature Rev , vol.6 , pp. 627-637
    • Tefferi, A.1    Skoda, R.2    Vardiman, J.W.3
  • 9
    • 74049112732 scopus 로고    scopus 로고
    • Prodromal myeloproliferative neoplasms: The 2008 WHO classification
    • Kvasnicka HM, Thiele J: Prodromal myeloproliferative neoplasms: the 2008 WHO classification. Am J Hematol 2010, 85:62-69
    • (2010) Am J Hematol , vol.85 , pp. 62-69
    • Kvasnicka, H.M.1    Thiele, J.2
  • 10
    • 33745079673 scopus 로고    scopus 로고
    • Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: A forgotten pearl
    • DOI 10.1016/j.beha.2005.07.015, PII S1521692605001027
    • Thiele J, Kvasnicka HM, Vardiman J: Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol 2006, 19:413-437 (Pubitemid 43884244)
    • (2006) Best Practice and Research: Clinical Haematology , vol.19 , Issue.3 , pp. 413-437
    • Thiele, J.1    Kvasnicka, H.M.2    Vardiman, J.3
  • 13
    • 44349140532 scopus 로고    scopus 로고
    • Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapy
    • Tefferi A: Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008, 83:491-497
    • (2008) Am J Hematol , vol.83 , pp. 491-497
    • Tefferi, A.1
  • 14
    • 0034720161 scopus 로고    scopus 로고
    • Myelofibrosis with myeloid metaplasia
    • Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342:1255-1265
    • (2000) N Engl J Med , vol.342 , pp. 1255-1265
    • Tefferi, A.1
  • 17
    • 77950388949 scopus 로고    scopus 로고
    • Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
    • Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, Skoda RC: Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010, 115:2003-2007
    • (2010) Blood , vol.115 , pp. 2003-2007
    • Schaub, F.X.1    Looser, R.2    Li, S.3    Hao-Shen, H.4    Lehmann, T.5    Tichelli, A.6    Skoda, R.C.7
  • 18
  • 20
    • 77958021645 scopus 로고    scopus 로고
    • LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2. IDH, JAK2 or MPL mutations
    • Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A: LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2. IDH, JAK2 or MPL mutations. Leukemia 2010, 24:1713-1718
    • (2010) Leukemia , vol.24 , pp. 1713-1718
    • Pardanani, A.1    Lasho, T.2    Finke, C.3    Oh, S.T.4    Gotlib, J.5    Tefferi, A.6
  • 21
    • 77956670899 scopus 로고    scopus 로고
    • LNK mutations in JAK2 mutationnegative erythrocytosis
    • Lasho TL, Pardanani A, Tefferi A: LNK mutations in JAK2 mutationnegative erythrocytosis. N Engl J Med 2010, 363:1189-1190
    • (2010) N Engl J Med , vol.363 , pp. 1189-1190
    • Lasho, T.L.1    Pardanani, A.2    Tefferi, A.3
  • 30
  • 31
    • 73649142039 scopus 로고    scopus 로고
    • ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1
    • Lee SW, Cho YS, Na JM, Park UH, Kang M, Kim EJ, Um SJ: ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1. J Biol Chem 2010, 285:18-29
    • (2010) J Biol Chem , vol.285 , pp. 18-29
    • Lee, S.W.1    Cho, Y.S.2    Na, J.M.3    Park, U.H.4    Kang, M.5    Kim, E.J.6    Um, S.J.7
  • 33
    • 79951865273 scopus 로고    scopus 로고
    • Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
    • abstract
    • Abdel-Wahab O, Pardanani A, Patel J, Lasho T, Heguy A, Levine R, Tefferi A: Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms (abstract). Blood 2010, 116:3070
    • (2010) Blood , vol.116 , pp. 3070
    • Abdel-Wahab, O.1    Pardanani, A.2    Patel, J.3    Lasho, T.4    Heguy, A.5    Levine, R.6    Tefferi, A.7
  • 36
    • 79960248721 scopus 로고    scopus 로고
    • DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms (letter to the editor)
    • Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A: DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms (letter to the editor). Leukemia 2011, 25:1219-1220
    • (2011) Leukemia , vol.25 , pp. 1219-1220
    • Abdel-Wahab, O.1    Pardanani, A.2    Rampal, R.3    Lasho, T.L.4    Levine, R.L.5    Tefferi, A.6
  • 40
    • 47649123488 scopus 로고    scopus 로고
    • Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: A critical reappraisal
    • Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A: Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22:1299-1307
    • (2008) Leukemia , vol.22 , pp. 1299-1307
    • Vannucchi, A.M.1    Antonioli, E.2    Guglielmelli, P.3    Pardanani, A.4    Tefferi, A.5
  • 41
    • 21344440357 scopus 로고    scopus 로고
    • The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes
    • DOI 10.1182/blood-2005-03-1183
    • Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207-1209 (Pubitemid 41129580)
    • (2005) Blood , vol.106 , Issue.4 , pp. 1207-1209
    • Steensma, D.P.1    Dewald, G.W.2    Lasho, T.L.3    Powell, H.L.4    McClure, R.F.5    Levine, R.L.6    Gilliland, D.G.7    Tefferi, A.8
  • 43
    • 67049173799 scopus 로고    scopus 로고
    • JAK2V617F mutation for the early diagnosis of Phmyeloproliferative neoplasms in patients with venous thromboembolism: A meta-analysis
    • Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W: JAK2V617F mutation for the early diagnosis of Phmyeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009, 113:5617-5623
    • (2009) Blood , vol.113 , pp. 5617-5623
    • Dentali, F.1    Squizzato, A.2    Brivio, L.3    Appio, L.4    Campiotti, L.5    Crowther, M.6    Grandi, A.M.7    Ageno, W.8
  • 44
    • 42149140574 scopus 로고    scopus 로고
    • JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: Assessment of value in a series of 664 consecutive patients
    • DOI 10.4065/83.4.457
    • Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A: JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008, 83:457-459 (Pubitemid 351536475)
    • (2008) Mayo Clinic Proceedings , vol.83 , Issue.4 , pp. 457-459
    • Pardanani, A.1    Lasho, T.L.2    Hussein, K.3    Schwager, S.M.4    Finke, C.M.5    Pruthi, R.K.6    Tefferi, A.7
  • 45
    • 34447625222 scopus 로고    scopus 로고
    • JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder [6]
    • DOI 10.1038/sj.leu.2404710, PII 2404710
    • Pardanani A, Lasho TL, Schwager S, Finke C, Hussein K, Pruthi RK, Tefferi A: JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder (letter to the editor). Leukemia 2007, 21:1828-1829 (Pubitemid 47086776)
    • (2007) Leukemia , vol.21 , Issue.8 , pp. 1828-1829
    • Pardanani, A.1    Lasho, T.L.2    Schwager, S.3    Finke, C.4    Hussein, K.5    Pruthi, R.K.6    Tefferi, A.7
  • 46
    • 34548128326 scopus 로고    scopus 로고
    • Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
    • DOI 10.1038/sj.leu.2404810, PII 2404810
    • Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A: Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007, 21:1960-1963 (Pubitemid 47299970)
    • (2007) Leukemia , vol.21 , Issue.9 , pp. 1960-1963
    • Pardanani, A.1    Lasho, T.L.2    Finke, C.3    Hanson, C.A.4    Tefferi, A.5
  • 47
    • 38349025467 scopus 로고    scopus 로고
    • Quantitative assessment of the JAK2 V617F allele burden: Equivalent levels in peripheral blood and bone marrow (letter to the editor)
    • Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC: Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow (letter to the editor). Leukemia 2008, 22:194-195
    • (2008) Leukemia , vol.22 , pp. 194-195
    • Larsen, T.S.1    Pallisgaard, N.2    Moller, M.B.3    Hasselbalch, H.C.4
  • 50
    • 77950445335 scopus 로고    scopus 로고
    • Is the JAK2(V617F) mutation detectable in healthy volunteers? (letter to the editor)
    • Martinaud C, Brisou P, Mozziconacci MJ: Is the JAK2(V617F) mutation detectable in healthy volunteers? (letter to the editor). Am J Hematol 2010, 85:287-288
    • (2010) Am J Hematol , vol.85 , pp. 287-288
    • Martinaud, C.1    Brisou, P.2    Mozziconacci, M.J.3
  • 52
    • 33749358349 scopus 로고    scopus 로고
    • Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
    • DOI 10.1182/blood-2006-04-018259
    • Scott LM, Scott MA, Campbell PJ, Green AR: Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 108:2435-2437 (Pubitemid 44497530)
    • (2006) Blood , vol.108 , Issue.7 , pp. 2435-2437
    • Scott, L.M.1    Scott, M.A.2    Campbell, P.J.3    Green, A.R.4
  • 55
    • 34447634117 scopus 로고    scopus 로고
    • Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: Cytogenetic and JAK2V617F molecular remissions [5]
    • DOI 10.1038/sj.leu.2404711, PII 2404711
    • Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA: Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions (letter to the editor). Leukemia 2007, 21:1827-1828 (Pubitemid 47086775)
    • (2007) Leukemia , vol.21 , Issue.8 , pp. 1827-1828
    • Tefferi, A.1    Lasho, T.L.2    Mesa, R.A.3    Pardanani, A.4    Ketterling, R.P.5    Hanson, C.A.6
  • 56
    • 33846880278 scopus 로고    scopus 로고
    • Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
    • DOI 10.1182/blood-2006-08-039909
    • Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M, Reiter A, Zabelina T, Zander AR, Fehse B: Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321 (Pubitemid 46220685)
    • (2007) Blood , vol.109 , Issue.3 , pp. 1316-1321
    • Kroger, N.1    Badbaran, A.2    Holler, E.3    Hahn, J.4    Kobbe, G.5    Bornhauser, M.6    Reiter, A.7    Zabelina, T.8    Zander, A.R.9    Fehse, B.10
  • 57
    • 77956439565 scopus 로고    scopus 로고
    • A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
    • Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M: A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010, 24:1574-1579
    • (2010) Leukemia , vol.24 , pp. 1574-1579
    • Passamonti, F.1    Rumi, E.2    Pietra, D.3    Elena, C.4    Boveri, E.5    Arcaini, L.6    Roncoroni, E.7    Astori, C.8    Merli, M.9    Boggi, S.10    Pascutto, C.11    Lazzarino, M.12    Cazzola, M.13
  • 58
    • 42449124578 scopus 로고    scopus 로고
    • Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
    • DOI 10.1038/sj.leu.2405097, PII 2405097
    • Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A: Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008, 22:756-761 (Pubitemid 351559282)
    • (2008) Leukemia , vol.22 , Issue.4 , pp. 756-761
    • Tefferi, A.1    Lasho, T.L.2    Huang, J.3    Finke, C.4    Mesa, R.A.5    Li, C.Y.6    Wu, W.7    Hanson, C.A.8    Pardanani, A.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.